Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and significant shareholder changes, while showing positive financial performance in its recent quarterly report [1][3][5]. Shareholder Changes - BioVeda China RMB Investment Limited reduced its holdings by 966,600 shares, accounting for 0.7055% of the total share capital, during a period when the company's stock price fell by 14.62% [3][6]. - As of September 30, 2025, the number of shareholders increased to 9,862, a rise of 15.44% compared to June 30, 2025, with the average shareholding decreasing from 16,000 shares to 13,900 shares [4][8]. Financial Performance - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [5][8]. - In the third quarter alone, the company achieved a main revenue of 56.02 million yuan, reflecting a year-on-year growth of 16.54%, and a net profit of 5.97 million yuan, which is a 237.64% increase compared to the same period last year [5][8]. - The company's debt ratio stands at 6.22%, with a gross profit margin of 68.9% [5]. Company Announcements - Aojing Medical has completed the reduction plan by BioVeda, which involved selling 1,355,515 shares at prices ranging from 23.00 to 28.12 yuan per share, totaling approximately 33.55 million yuan [6][8]. - The company has concluded the fundraising project for "Mineralized Collagen/Polyester Artificial Bone and Collagen Sponge R&D," with a surplus of 523,800 yuan intended for permanent replenishment of working capital [7][8].

Core Viewpoint - The company has announced the completion of certain fundraising projects and the permanent allocation of surplus funds to supplement working capital, along with the cancellation of related fundraising accounts [8][9][12]. Financial Data - The company reported that the total amount raised from the public offering was approximately RMB 547.67 million, with net proceeds after deducting issuance costs amounting to approximately RMB 500.82 million [8]. - The company has stated that the fundraising project "Mineralized Collagen/Polyester Artificial Bone and Collagen Sponge R&D Project" has been completed, and the surplus funds will be used to permanently supplement working capital [9][12]. Fundraising Project Details - The company has decided to conclude the aforementioned fundraising project and will cancel the related fundraising accounts, which will not affect the normal operation of the fundraising project [13]. - The surplus funds amount to approximately RMB 523,800, including interest income, which will be used for daily operational activities [12]. Opinions from Supervisory and Sponsoring Institutions - The supervisory board believes that the decision to conclude certain fundraising projects and allocate surplus funds is beneficial for improving the efficiency of fund usage and reducing financial costs, aligning with the interests of all shareholders [14]. - The sponsoring institution, Huatai United Securities, has confirmed that the decision-making process was properly followed and supports the allocation of surplus funds as a prudent decision that optimizes resource allocation [15].